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Simple Summary: Bladder cancer is one of the most common malignancies in the United States
with a majority of patients diagnosed with non-muscle invasive bladder cancer (NMIBC). Despite
early detection and regular surveillance of most cases, recurrence and progression rates remain high.
The aim of our systematic review and meta-analysis was to compare the sensitivity, specificity, and
oncologic outcomes of photodynamic diagnosis (PDD) fluorescence, narrow band imaging (NBI),
and conventional white light cystoscopy (WLC) in detecting NMIBC. Through the collection of
prospective and randomized controlled trials, we demonstrated that tumor resection with either PDD
and NBI exhibited greater diagnostic sensitivity compared to WLC alone. Our findings underscore
the value of integrating these enhanced technologies as a part of the standard care for patients with
suspected or confirmed NMIBC.
Abstract: Despite early detection and regular surveillance of non-muscle invasive bladder can-
cer (NMIBC), recurrence and progression rates remain exceedingly high for this highly prevalent
malignancy. Limited visualization of malignant lesions with standard cystoscopy and associated
false-negative biopsy rates have been the driving force for investigating alternative and adjunctive
technologies for improved cystoscopy. The aim of our systematic review and meta-analysis was
to compare the sensitivity, specificity, and oncologic outcomes of photodynamic diagnosis (PDD)
fluorescence, narrow band imaging (NBI), and conventional white light cystoscopy (WLC) in de-
tecting NMIBC. Out of 1,087 studies reviewed, 17 prospective non-randomized and randomized
controlled trials met inclusion criteria for the study. We demonstrated that tumor resection with
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either PDD and NBI exhibited lower recurrence rates and greater diagnostic sensitivity compared to
WLC alone. NBI demonstrated superior disease sensitivity and specificity as compared to WLC and
an overall greater hierarchical summary receiver operative characteristic. Our findings are consistent
with emerging guidelines and underscore the value of integrating these enhanced technologies as a
part of the standard care for patients with suspected or confirmed NMIBC.
Keywords: blue light cystoscopy; accuracy meta-analysis; bladder cancer; cystoscopy; narrow band
imaging; photodynamic diagnosis fluorescence; PDD; hexaminolevulinate; HAL; 5-aminolaevulinic
acid; 5-ALA
1. Introduction
Bladder cancer (BCa) represents one of the most common malignancies diagnosed
in both males and females with a projected 2021 incidence of 83,730 and mortality of
17,200 in the United States [1]. Approximately 70% of BCa diagnoses present with non-
muscle-invasive BCa (NMIBC): Ta, T1, and carcinoma in situ (CIS) [2]. Although BCa is
typically detected in the early stages, there are significant five-year recurrence and pro-
gression rates of 78% and 45%, respectively [3]. Given the high risk of both recurrence
and progression, regular cystoscopic surveillance is considered the standard of care fol-
lowing the first transurethral resection of a bladder tumor (TURBT) [4]. Although TURBT
with conventional white light cystoscopy (WLC) is the prevailing method for detecting
urothelial tumors [4], WLC has a false-negative rate of 10–20% due to limited lesion vi-
sualization [5]. As a result, novel technologies are under development to improve lesion
detection, diagnostic accuracy, and prognosis.
The so-called “blue light cystoscopy”, also known as photodynamic diagnosis (PDD)
fluorescence cystoscopy, was first described in 1964 [6] and due to its effectiveness in im-
proving cancer detection and clinical outcomes, it has since gained popularity as an adjunct
to WLC [7,8]. PDD is preceded by intravesical instillation of 5-aminolaevulinic acid (5-
ALA) or hexaminolevulinate (HAL), photosensitizing prodrugs that preferentially induce
the accumulation of porphyrins, most notably protoporphyrin IX, in rapidly proliferating
urothelial cells. Illumination of the bladder wall with blue light (380–450 nm) causes cells
with accumulated protoporphyrin to turn fluoresce red, aiding in neoplasm identification.
Another imaging technique known as narrow band imaging (NBI) involves illuminat-
ing the bladder wall with filtered white light. The emitted wavelengths are absorbed by
hemoglobin and thus penetrate the urothelial surface and enhance the visualization of
the mucosal vasculature, especially neoangiogenic urothelial tumors [4]. While several
clinical trials have been published examining the clinical outcomes associated with NBI,
PDD, and WLC, there are no meta-analyses comparing the utility and outcomes of all
three modalities.
In this study, we present a comprehensive systematic review and diagnostic meta-
analysis comparing the diagnostic accuracy of WLC, NBI, and PDD in patients with BCa.
2. Materials and Methods
This study was performed following guidelines set out by the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-analysis) statement [9]. The study is
registered in PROSPERO (CRD42017069333).
2.1. Search Strategy and Selection Criteria
We identified English-only prospective clinical trials of NBI, PDD, and WLC in blad-
der cancer through a search of PubMed/MEDLINE, Scopus, and Web of Science with
the terms “5- aminolevulinate (or 5-ALA) blue-light cystoscopy” OR “ Hexaminolevulinate
( or HAL) blue-light cystoscopy” OR “Narrow band imaging cystoscopy” AND “bladder cancer”
(Appendix A). We included trials published June 2021 or earlier that report diagnostic
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outcomes comparing 5-aminolevulinate (5-ALA) blue-light cystoscopy OR Hexaminolevulinate
(HAL) blue-light cystoscopy OR Narrow Band Imaging (NBI) cystoscopy vs. white light cystoscopy
(WLC). Eligible studies were divided into 3 categories: (1) prospective clinical trials com-
paring 5-ALA vs. WLC; (2) prospective clinical trials comparing HAL vs. WLC; and (3)
prospective clinical trials comparing NBI vs. WLC. Papers not reporting the diagnostic
accuracy of the techniques were excluded from the meta-analysis. Editorials, commentaries,
meeting abstracts, reviews, meta-analyses, book chapters, and studies reporting experi-
ments involving human cadavers or animals were excluded from this review. References
were manually reviewed to identify additional studies of interest.
2.2. Selection Studies and Quality Assessment
Two of the study authors (GEC and GIR) independently reviewed the literature
according to the previously described inclusion and exclusion criteria. All discrepancies
in study inclusion or exclusion were jointly reviewed until agreement was reached on the
full list of articles. In instances where an institution or group published multiple papers
derived from analyses of a single dataset, we carefully avoided duplicate data and extracted
the most up-to-date parameters and endpoints of interest. Similarly, multi-site studies
were excluded if the data and results overlapped with an included publication from a
contributing center.
Following the Cochrane Handbook for Systematic Reviews, the risk of bias and study
applicability were assessed using the validated Quality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) scoring system [10] and the Cochrane Collaboration’s Tool. Quality
assessment of the studies was independently performed by two reviewers (GEC and GIR).
All papers were classified according to their level of evidence (LOE) for therapeutic
studies: systematic review of randomized trials or n-of-1 trials (level 1); randomized trials
or observational studies with dramatic effect (level 2); non-randomized controlled cohort
or follow-up studies (level 3); case series, case-control studies, or historically-controlled
studies (level 4); and mechanism-based reasoning (level 5).
2.3. Endpoints of Interests
The primary endpoint of interest was the per-lesion diagnostic accuracy of NBI vs.
WLC and PDD vs. WLC. This included the cumulative tumor detection rate and false-
positive rate stratified as appropriate for each diagnostic approach. These calculations were
performed on lesion-level data.
2.4. Statistical Analysis
The cumulative meta-analysis of trials comparing NBI vs. WLC, 5-ALA vs. WLC,
and HAL vs. WLC was conducted using Review Manager® 5.3 (Cochrane Collaboration,
Oxford, UK). We performed a comparative baseline characteristics analysis to evaluate
statistically significant differences between patients who underwent 5-ALA, HAL, NBI, or
WLC. The sensitivity analysis comparing HAL vs. WLC was carried out. All results were
reported with 95% confidential intervals.
As part of the primary endpoint of the meta-analysis, we generated forest plots to
assess result variability and heterogeneity, and then generated a receiver operating charac-
teristic (ROC) curve to assess sensitivity and specificity. The ln(OR) and SE[ln(OR)] were cal-
culated through a first-order Taylor series conversion, where SE[ln(OR)] = (1/OR) *SE[OR].
Primary outcomes are presented as pooled estimates of sensitivity and specificity
with 95% confidence intervals (CIs) for detecting bladder cancer. Random or fixed effect
were used in the case or absence of heterogeneity, respectively. To provide this result, we
used the “metandi” command in Stata v.12.1 (StataCorp, College Station, TX, USA). The
summary receiver operating characteristic (ROC) curve was plotted using this procedure.
The pooled estimates for sensitivity and specificity were based on bivariate analysis.
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3. Results
3.1. Literature Search
Our initial systematic literature search yielded 1610 articles, 523 of which were dupli-
cate studies. Screening of the remaining 1087 titles and abstracts generated 318 potentially
eligible original articles. After careful review, 17 studies were retrieved and included in
the quantitative analysis. Table 1 includes six studies comparing NBI vs. WLC [11–16]:
one RCT (LOE 2) and five prospective non-RCTs (LOE 3). Table 2 includes three studies
comparing 5-ALA vs. WLC [17–19], of which none were RCTs (LOE 2) and three were
prospective non-RCTs (LOE 3), as well as eight studies comparing HAL vs. WLC [20–27],
of which three were RCTs (LOE 2) and six were prospective non-RCTs (LOE 3). The study
selection process is summarized in Figure 1.
Table 1. Studies comparing narrowband imaging vs. white light cystoscopy. Abbreviations: RTC, randomized clinical trial;
LOE, level of evidence; NBI, narrowband imaging; and WLC, white light cystoscopy. The data reported are per patient-level.
Study Year Institution Type of Study LOE Type ofCystoscopy
Number of
Samples
Ye et al. [16] 2013 Huazhong University of Scienceand Technology, Wuhan, China RTC 2
NBI 300
WLC 300






Song et al. [14] 2014
Department of Urology,





Shen et al. [13] 2012






Kobatake et al. [12] 2015
Department of Urology,





Cauberg et al. [11] 2010







The overall quality of the studies is reported in Figure 2. None of the individual
studies explicitly followed the Standards for Reporting of Diagnostic Accuracy (STARD)
guidelines. All studies were analyzed according to the QUADAS-2 criteria. Within the
patient selection domain, only one study had a high risk of bias due to inappropriate
selection criteria [19]. All studies included were prospective. In the majority of studies,
there was a high risk of bias in the index test domain due to the knowledge of results,
potentially influencing the interpretation of the results. Within the reference standard and
the flow and timing domains, all studies were determined to have a low risk of bias. The
overall median QUADAS-2 score was 10.0 (range: 8.0–14.0).
3.3. Cumulative Accuracy Meta-Analysis of Comparative Studies Reporting Diagnostic Accuracy
The pooled data showed a sensitivity of 0.96 (95% CI = 0.93–0.98), 0.93 (95% CI = 0.87–0.96),
and 0.71 (95% CI = 0.66–0.76), and a pooled specificity of 0.65 (95% CI = 0.54–0.75), 0.63 (95%
CI = 0.51–0.73), and 0.71 (95% CI = 0.57–0.81) for NBI, PDD, and WLC, respectively (Figure 3).
The derived area under the curve (AUC) from the hierarchical summary receiver operating
characteristic (HSROC) showed an accuracy of 0.90 (95% CI = 0.92–0.98), 0.88 (95% CI = 0.85–0.90),
and 0.76 (95% CI = 0.72–0.79) for NBI, PDD, and WLC, respectively (Figure 4).
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Table 2. Studies comparing photodynamic diagnosis vs. white light cystoscopy. Abbreviations: RTC, randomized clinical
trial; LOE, level of evidence; 5- ALA, 5-aminolevulinic acid; HAL, hexaminolevulinate; and WLC, white light cystoscopy.
The data reported are per patient-level.




Draga et al. [17] 2009
Departments of Urology, Medical
Physics, and Pathology, University
Medical Center Utrecht, Utrecht,
the Netherlands Medical
Center Utrecht
Prospective 3 5-ALA 1874
WLC 1874
Schneeweiss et al. [19] 1999
Department of Epidemiology,
Harvard University School of
Public Health, Boston,
Massachusetts
Prospective 3 5-ALA 328
WLC 328
Burgues et al. [20] 2011
Department of Urology, Caritas-St.
Josef Medical Center, University
of Regensburg,
Regensburg, Germany
RCT 2 HAL 1659
WLC 1659
Nakai et al. [18] 2018





Jichlinski et al. [21] 2003
Department of Urology and
Institute of Pathology, CHUV
University-Hospital
Prospective 3 HAL 421
WLC 414
Jocahm et al. [22] 2005
Departments of Urology,
University of Schleswig-Holstein,
Campus Lübeck (DJ), Lübeck
RCT 2 HAL 499
WLC 343
Lapini et al. [23] 2012
Department of Urology (PJ, H-JL)
and Institute of Pathology (LG),
CHUV University-Hospital
Prospective 3 HAL 234
WLC 234
Lee et al. [24] 2012




Prospective 3 HAL 110
WLC 134







Ray et al. [26] 2010
Urology Centre, Guy and St.











Chi-square evaluation of the variation due to study heterogeneity was as follows:
NBI I2 93.0% (95% CI = 87.0–99.0; p < 0.01), 99% (95% CI = 99.0–100.0; p < 0.01), and 100%
(95% CI = 100.0–100.0; p < 0.01).
The diagnostic OR for NBI, PDD, and WLC were 39.0 (95% CI = 24.0–64.0), 21.0
(95% CI = 14.0–32.0), and 6.0 (95% CI = 3.0–10.0), respectively.
The positive and negative likelihood ratio were 2.6 (95% CI = 1.7–4.0) and 0.07
(95% CI = 0.04–0.10] for NBI; 2.5 (95% CI = 1.9–3.3) and 0.12 (95% CI = 0.08–0.19) for
PDD; and 2.4 (95% CI = 1.6–3.6) and 0.41 (95% CI = 0.34–0.50) for WLC.
Figure 5 shows the funnel plot of Deeks et al. [28], demonstrating low risk of bias for
NBI (p = 0.41), PDD (p = 0.26), and WLC (p = 0.22).
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3.4. Subset Diagnostic Meta-Analysis of Studies Comparing HAL-PDD vs. WLC
As HAL-PDD have shown superiority over 5-ALA-PDD, we performed a sensitivity
analysis including a total of eight studies that investigated the diagnostic a curacy of
HAL-PDD vs. WLC.
The poole data showed a sensitivity of 0.93 (95% CI = 0.85– .97) and 0.73
(95% CI = 0.66–0.79), and a pooled specificity of .64 (95% CI = 0.50–0.76) and 69
(95% CI = 0.49–0.84) for HAL-PDD and WLC, respectively (Figure 6). The derived area
under the curve (AUC) from th h erarchical summary r ceiver operating characteristic
(HSROC) showed an accuracy of 0.88 (95% CI = 0.85–0.90) and 0.77 (95% CI = 0.73–0.80) for
HAL-PDD and WLC, respectively (Figure 6).
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The diagnostic OR for HAL-PDD and WLC were 24.0 (95% CI = 14.0–44.0) and 6.0
(95% CI = 3.0–13.0), respectively, while the positive and negative likelihood ratios were
2.6(95% CI = 1.9- 3.6) and 0.11 (95% CI = 0.06–0.20] for HAL-PDD and 2.4 (95% CI = 1.4–4.1)
a d 0.39 (95% CI = 0.29–0.51) fo WLC.
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4. Discussion
The cornerstone of diagnosis and surveillance of NMIBC is thorough cystoscopic
bladder examination with histological examination of biopsies or resected tissue. While
the use of WLC alone can lead to inaccurate diagnoses due to the limited visualization
of neoplastic lesions [29], the role of PDD or NBI in increasing the accuracy of WLC and
NMIBC management is still being explored. Despite evidence of a statistically significant
improvement in the detection of primary and recurrent BCa with PDD and NBI, concerns
have been raised regarding potential biases. These biases include observer bias, lack of
blinding, and, in cases where NBI or PDD followed WLC with the same urologist, increased
detection rate due to “second look” inspection of the bladder [4,13].
In the present study, we found that WLC was inferior to PDD and NBI in terms of
both diagnostic OR and sensitivity. Based on the direct comparison, there were increased
diagnostic ORs and sensitivities of NBI and PDD vs. WLC. The average sensitivity of NBI
and PDD was 0.96 (0.93–0.98) and 0.93 (0.87–0.96), respectively, while that of WLC was 0.71
(0.66–0.76). The average diagnostic OR was 39 (24.0–64.0) and 21.0 (14.0–32.0) for NBI and
PDD, respectively, and that of WLC was 6.0 (95% CI = 3.0–10.0). When the analysis was
restricted to the studies comparing HAL-PDD vs. WLC only, the HAL-PDD cystoscopies
were more sensitive than WLC (0.93 (95% CI = 0.85–0.97) vs. 0.73 (95% CI = 0.66–0.79))
with a higher diagnostic OR (24.0 (95% CI = 14.0–44.0) vs. 6.0 (95% CI = 3.0–13.0)).
A previous network intervention-meta-analysis of outcomes for TUR with PDD vs. NBI
showed that the recurrence rate of cancers resected with 5-ALA-based PDD was significantly
lower than those resected using HAL-based PDD (OR = 0.48 [95% CI = 0.26–0.95]) but was
not significantly different than those resected with NBI (OR = 0.53 [95% CI = 0.26–1.09]).
Similarly, the difference in the recurrence rate of cancers resected using HAL-based PDD vs.
NBI was not statistically significant (OR = 1.11 [95% CI = 0.55–2.1]). Overall, NMIBC lesions
resected with 5-ALA-based PDD, HAL-based PDD, and NBI recurred at a lower rate than
those resected using WLC. Yet, no statistically significant difference in the progression rate
was appreciated between cancers resected by all the methods investigated [30].
Consistent with our results, a previous meta-analysis by Xiong et al. showed that in
a per-lesion analysis, the pooled additional detection rate of NBI for NMIBC was 18.6%
greater than WLC [31]. The per-patient pooled sensitivity of NBI was significantly greater
than WLC (95.8% vs. 81.6%, respectively) [31]. Furthermore, NBI significantly reduced the
recurrence rate of bladder cancer with a pooled RR value of 0.43 (95% CI = 0.23–0.79) and
0.81 (95% CI = 0.69–0.95) at three- and twelve-months post-resection, respectively [31].
Chen et al. recently published a meta-analysis of observational studies assessing the
diagnostic performance of NBI, 5-ALA, and HAL, concluding that the mage technique
based transurethral resection (NBI, HAL, and 5-ALA) showed a diagnostic advantage [32].
In our systematic review, we have performed a “per lesion level meta-analysis’ of only
prospective studies and provided the reference with the WLC.
However, it is worth noting that individual studies of the utility of NBI as an adjunct
to WLC are quite variable. A single-center, randomized, and non-blinded study comparing
same-session second-look with NBI and WLC found that although NBI detected a signif-
icantly greater number of lesions than WLC alone (p = 0.035), there was no statistically
significant difference in recurrence (p = 0.373) or overall tumor detection (p = 0.137) [33].
The forthcoming Cochrane review of RCTs involving TURBT with NBI vs. WLC by Lai
et al. may offer clarity concerning long-term clinical and oncologic outcomes [34].
The improved accuracy of NBI over WLC can be attributed to differences in the
associated wavelengths of light. The spectrum of light used in NBI is relatively narrow
(from 415 nm ultraviolet to 540 nm green) when compared to WLC, which includes a
wide, non-standardized spectrum of light. In NBI, the visualization of microvascular
structures is enhanced as the blue to green wavelengths penetrate superficial layers of
the mucosa [35]. Typical limitations of NBI, such as blood altering light penetration and
a procedural learning curve, do not seem to play a role in the cystoscopy for bladder
cancer [36].
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In comparison, PDD requires the instillation of prodrugs that, due to differences in
enzymatic activity between malignant and benign tissues, lead to a selective accumulation
of the fluorescent protoporphyrin IX in dysplastic cells [37,38]. The two most common
agents used for PDD are 5-ALA and HAL, prodrugs that exhibit no photoactivity until
they are metabolized in urothelial cells. In line with this mechanism, an analysis of a
prospective US registry of PDD with HAL in combination with WLC revealed an increase
in the detection of clinically relevant tumors with an impact on management [27]. Moreover,
patient smoking status has not been found to impact recurrence rates in patients followed
with PDD, though evidence of the impact of smoking on recurrence with WLC surveillance
is equivocal [39]. A phase III prospective study of PDD with HAL found that approximately
20.6% of malignant lesions were only detected with PDD and not WLC, leading to a
US consensus statement recommending PDD with HAL for surveillance cystoscopy of
NMIBC [8,40]. Adherence to this consensus recommendation for NMIBC surveillance
has shown that the use of PDD led to the detection of 33% cancerous lesions over WLC
alone [41].
In addition to clinical outcomes, we also believe it is essential to consider the economic
impact of increasingly complex technology. Although PDD has a higher upfront cost,
previous studies have found that, due to improved tumor detection and more complete
resection, PDD is more cost-effective than WLC in the long term [37,42]. Even in the
short term, Smith et al. found that patients were willing to pay out-of-pocket despite
the increased cost of PDD and demonstrated positive perceptions of PDD regardless of
oncologic outcomes [43]. Sievert et al. found that the TURB cost for conventional WLC was
EUR 1527.11 (USD 2031.06), while PDD had a cost of EUR 1386.83 (USD 1844.48) with a
net cost saving of EUR 140.28 (USD 168.57) in a German health system [44]. Although not
formally reviewed in our study, we would predict that the cost comparison of NBI to WLC
would yield a similar result. The direct fixed equipment costs of NBI and PDD are likely
comparable, though NBI would be expected to have lower direct variable costs as it does
not require pre-procedural catheters and drug instillation.
Considering the findings of the present study, as well as the comparable publications
and economic modeling, it is reasonable to recommend cystoscopy with either PDD or
NBI for TURBT and surveillance of NMIBC. Currently, both the European Association of
Urology (EAU) and the American Urological Association (AUA) recommend performing
PDD cystoscopy/TURB (Grade B) to increase detection and recurrent lesions [4,45]. At
this time, only the AUA guidelines recommend consideration of NBI (Grade C) to increase
detection and decrease recurrence of NMIBC [4,45].
A 2019 survey assessing discordance between EAU guidelines for the management
of NMIBC and clinical practice found that although a majority of European physicians
endorse guideline adherence, a minority of patients receive PDD [46]. In patients who
receive treatment for NMIBC in one of the surveyed European countries, the portion of
patients undergoing PDD-TURB ranged from 1% to 40% (mean 15%) in low-risk BCa and
from 4% to 55% (mean 28%) in high-risk BCa [46]. The relatively low and simultaneously
heterogeneous adherence to EAU guidelines highlights a putative difference in the health
policy between these countries and areas for future improvement.
While the primary strength of the present study is the inclusion of only prospective
and randomized clinical studies, there several limitations exist. Firstly, the overall quality
of the diagnostic studies was moderate and variable (median 10.0; range of 4 to 14),
demonstrating the presence of bias in the included studies. We believe that observer and
lack of blinding in the included studies may represent the most significant potential source
of bias in the present study. Secondly, we made an intentional decision to conduct this
meta-analysis at a per-lesion level rather than on a per-patient basis in order to increase the
precision of sensitivity and specificity calculations for each diagnostic procedure and in the
attempt to reduce the heterogeneity between the studies’ settings. Thirdly, cystoscopy is
dependent on operator experience, which could not be accounted for in this study due to a
lack of data. Finally, we have performed a meta-analysis of diagnostic test accuracy studies,
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which differs from the previous meta-analysis of therapeutic/interventional studies in
which it was required to simultaneously analyze a pair of two outcome measures such
as sensitivity and specificity rather than of a single outcome. It is worthy to note that the
meta-analysis of diagnostic test accuracy studies is a more sensitive tool when comparing
different diagnostic tests.
Given our findings we believe that ongoing interventional trials will continue to
strengthen evidence supporting adjunct technologies for NMIBC diagnosis, surveillance,
and management. Future research is needed to directly evaluate differences in the clinical
outcomes and economic burden between PDD and NBI. We anticipate the development
of novel techniques based on PDD and NBI. In PDD, there is an ongoing pilot study
(NCT03058705) assessing a highly sensitive multi-spectral imaging modality (near infrared
fluorescence or NIRF) with the potential to speed up the detection of bladder cancer
fluorescence after the infusion of hexaminolevulinate compared to the standard PDD. Both
PDD and NBI are also being evaluated for their potential to evaluate surgical margins
intraoperatively and thereby improve long-term outcomes for patients with NMIBC [36,47].
5. Conclusions
In this meta-analysis, we demonstrated that TURBT with either PDD or NBI exhibited
a greater diagnostic sensitivity compared to WLC. Our findings underscore the value of
integrating these enhanced technologies as a part of the standard care for patients with
suspected or confirmed NMIBC.
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Appendix A
Appendix A.1. Search Criteria and Translational Terms Used for the Literature Review
Search:(((((narrow band imaging) AND (bladder cancer)) OR ((NBI) AND (bladder
cancer))) OR ((((Hexaminolevulinate) AND (bladder cancer)) OR ((5-aminolevulinate)
AND (bladder cancer))) OR ((blue light cystoscopy) AND (bladder cancer)))) OR ((5-ALA)
AND (bladder cancer))) OR ((HAL) AND (bladder cancer))
((“narrow band imaging” [MeSH Terms] OR (“narrow” [All Fields] AND “band”
[All Fields] AND “imaging” [All Fields]) OR “narrow band imaging” [All Fields]) AND
(“urinary bladder neoplasms” [MeSH Terms] OR (“urinary” [All Fields] AND “bladder”
[All Fields] AND “neoplasms” [All Fields]) OR “urinary bladder neoplasms” [All Fields]
OR (“bladder” [All Fields] AND “cancer” [All Fields]) OR “bladder cancer” [All Fields]))
OR (“NBI” [All Fields] AND (“urinary bladder neoplasms” [MeSH Terms] OR (“urinary”
[All Fields] AND “bladder” [All Fields] AND “neoplasms” [All Fields]) OR “urinary blad-
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der neoplasms” [All Fields] OR (“bladder” [All Fields] AND “cancer” [All Fields]) OR
“bladder cancer” [All Fields])) OR (((“5 aminolevulinic acid hexyl ester” [Supplementary
Concept] OR “5 aminolevulinic acid hexyl ester” [All Fields] OR “hexaminolevulinate”
[All Fields]) AND (“urinary bladder neoplasms” [MeSH Terms] OR (“urinary” [All Fields]
AND “bladder” [All Fields] AND “neoplasms” [All Fields]) OR “urinary bladder neo-
plasms” [All Fields] OR (“bladder” [All Fields] AND “cancer” [All Fields]) OR “bladder
cancer” [All Fields])) OR ((“5 aminolaevulinate” [All Fields] OR “aminolevulinic acid”
[MeSH Terms] OR (“aminolevulinic” [All Fields] AND “acid” [All Fields]) OR “aminole-
vulinic acid” [All Fields] OR “5 aminolevulinate” [All Fields]) AND (“urinary bladder
neoplasms” [MeSH Terms] OR (“urinary” [All Fields] AND “bladder” [All Fields] AND
“neoplasms” [All Fields]) OR “urinary bladder neoplasms” [All Fields] OR (“bladder” [All
Fields] AND “cancer” [All Fields]) OR “bladder cancer” [All Fields])) OR (“blue” [All
Fields] AND (“light” [MeSH Terms] OR “light” [All Fields] OR “lighted” [All Fields] OR
“lights” [All Fields] OR “lighting” [MeSH Terms] OR “lighting” [All Fields] OR “lightings”
[All Fields] OR “lightness” [All Fields] OR “lightnesses” [All Fields]) AND (“cystoscopy”
[MeSH Terms] OR “cystoscopy” [All Fields] OR “cystoscopies” [All Fields]) AND (“uri-
nary bladder neoplasms” [MeSH Terms] OR (“urinary” [All Fields] AND “bladder” [All
Fields] AND “neoplasms” [All Fields]) OR “urinary bladder neoplasms” [All Fields] OR
(“bladder” [All Fields] AND “cancer” [All Fields]) OR “bladder cancer” [All Fields]))) OR
((“aminolevulinic acid” [MeSH Terms] OR (“aminolevulinic” [All Fields] AND “acid” [All
Fields]) OR “aminolevulinic acid” [All Fields] OR “5 ala” [All Fields]) AND (“urinary
bladder neoplasms” [MeSH Terms] OR (“urinary” [All Fields] AND “bladder” [All Fields]
AND “neoplasms” [All Fields]) OR “urinary bladder neoplasms” [All Fields] OR (“bladder”
[All Fields] AND “cancer” [All Fields]) OR “bladder cancer” [All Fields])) OR (“HAL” [All
Fields] AND (“urinary bladder neoplasms” [MeSH Terms] OR (“urinary” [All Fields] AND
“bladder” [All Fields] AND “neoplasms” [All Fields]) OR “urinary bladder neoplasms”
[All Fields] OR (“bladder” [All Fields] AND “cancer” [All Fields]) OR “bladder cancer”
[All Fields]))
Appendix A.2. Translations
narrow band imaging: “narrow band imaging” [MeSH Terms] OR (“narrow” [All
Fields] AND “band” [All Fields] AND “imaging” [All Fields]) OR “narrow band imaging”
[All Fields]
Hexaminolevulinate:”5-aminolevulinic acid hexyl ester” [Supplementary Concept]
OR “5-aminolevulinic acid hexyl ester” [All Fields] OR “hexaminolevulinate” [All Fields]
5-aminolevulinate:”5 aminolaevulinate” [All Fields] OR “aminolevulinic acid” [MeSH
Terms] OR (“aminolevulinic” [All Fields] AND “acid” [All Fields]) OR “aminolevulinic
acid” [All Fields] OR “5 aminolevulinate” [All Fields]
light:”light” [MeSH Terms] OR “light” [All Fields] OR “lighted” [All Fields] OR
“lights” [All Fields] OR “lighting” [MeSH Terms] OR “lighting” [All Fields] OR “lightings”
[All Fields] OR “lightness” [All Fields] OR “lightnesses” [All Fields]
cystoscopy:”cystoscopy” [MeSH Terms] OR “cystoscopy” [All Fields] OR “cysto-
scopies” [All Fields]
5-ALA:”aminolevulinic acid” [MeSH Terms] OR (“aminolevulinic” [All Fields] AND
“acid” [All Fields]) OR “aminolevulinic acid” [All Fields] OR “5 ala” [All Fields]
bladder cancer:”urinary bladder neoplasms” [MeSH Terms] OR (“urinary” [All Fields]
AND “bladder” [All Fields] AND “neoplasms” [All Fields]) OR “urinary bladder neo-
plasms” [All Fields] OR (“bladder” [All Fields] AND “cancer” [All Fields]) OR “bladder
cancer” [All Fields]
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